Clinical Trial Update: A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating brentuximab vedotin in combination with nivolumab for relapsed or refractory Hodgkin lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• nivolumab (nivolumab)

Snippet

Sponsor: Seagen Inc. | Conditions: Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-03-07